Buscar
Takeda Pharmaceutical Co Ltd
TAKAñadir a la lista de seguimiento
15.720USD
-0.120-0.76%
Cierre 06/24, 16:00（ET）Cotizaciones retrasadas 15 min
50.21BCap. mercado
40.98P/E TTM
Más Datos de Takeda Pharmaceutical Co Ltd Compañía
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Información de Takeda Pharmaceutical Co Ltd
Símbolo de cotizaciónTAK
Nombre de la empresaTakeda Pharmaceutical Co Ltd
Fecha de salida a bolsaJun 21, 2085
Director ejecutivoWeber (Christophe)
Número de empleados47455
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 21
Dirección4F
CiudadCHUO-KU
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísJapan
Código postal103-8668
Teléfono81332782111
Sitio Webhttps://www.takeda.com/
Símbolo de cotizaciónTAK
Fecha de salida a bolsaJun 21, 2085
Director ejecutivoWeber (Christophe)
Ejecutivos de Takeda Pharmaceutical Co Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
7.60K
--
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Takeda Pharmaceutical Co Ltd?
Los cinco principales accionistas de Takeda Pharmaceutical Co Ltd son: Dr. John M. Maraganore, Ph.D.
¿Cuántas instituciones poseen acciones de Takeda Pharmaceutical Co Ltd (TAK)?
A fecha de 2026Q1, 637 instituciones poseen acciones de Takeda Pharmaceutical Co Ltd, con un valor de mercado combinado de aproximadamente 85.31M, lo que representa el 2.70% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -8142483.00.
¿Cuál es la mayor fuente de ganancias de Takeda Pharmaceutical Co Ltd?
El 2026Q1, el segmento empresarial Gastrointestinal diseases generó la ganancia más alta para Takeda Pharmaceutical Co Ltd, ascendiendo a 385.81B y representando el 32.37% de la ganancia total.
